logo
Fannie and Freddie no longer require FICO. Will it help you get a mortgage?

Fannie and Freddie no longer require FICO. Will it help you get a mortgage?

USA Today11-07-2025
A regulator's decision to allow a big change to the way mortgages are underwritten is meeting a mixed reception from housing and finance professionals.
'Effective today, to increase competition to the Credit Score Ecosystem and consistent with President Trump's landslide mandate to lower costs, Fannie and Freddie will ALLOW lenders to use Vantage 4.0 Score,' Bill Pulte, the head of the Federal Housing Finance Agency (FHFA), tweeted on July 8.
FHFA oversees Fannie Mae and Freddie Mac, the two giant government-sponsored enterprises that guarantee nearly half of all U.S. mortgage debt. Fannie and Freddie buy loans from banks and other financial institutions, so when they change their processes, it matters to lenders around the country, and the borrowers they serve.
In this case, Pulte was referring to VantageScore, a company that offers credit scores – numerical representations of how likely a borrower is to repay a loan. Lenders who offer mortgages with the intention of selling them to Fannie or Freddie now have the option to use either VantageScore or to continue to use FICO, a competitor, to assess a borrower.
'FHFA's announcement to allow lenders to have a choice of credit score models to use when delivering loans to Fannie Mae and Freddie Mac could help to accomplish the goals of added competition in the credit score space and reduced consumer costs, if implemented correctly,' said the Mortgage Bankers Association, an industry group representing lenders, in a statement.
'We need more competition among credit bureaus and an end to monopolistic practices to lower prices and improve accuracy," Sharon Cornelissen, director of housing for the progressive Consumer Federation of America, told USA TODAY, in an email. "Director Pulte's action is a step in the right direction, and we hope he continues to work on reducing closing costs and broadening mortgage access for consumers.'
But some consumer advocates believe the introduction of VantageScore into the mortgage space will actually decrease competition by consolidating industry share more firmly in the hands of TransUnion, Experian and Equifax, the three credit bureaus, which own the company.
'The big three credit bureaus are basically a functional monopoly,' said Chi Chi Wu, director of consumer reporting and data advocacy at the National Consumer Law Center. 'If you want a mortgage, you have to pull all three reports. You have no choice. They created VantageScore to try to drive FICO out of the market because they want the whole market. FICO is the only independent actor.'
Ingmar Goldson, a Maryland-based consumer lawyer, echoed those beliefs. "Given that VantageScore is owned by the three major credit bureaus, I remain skeptical of any claims—whether from Fannie, Freddie, or the bureaus themselves—that this shift will truly benefit consumers in the long run," he told USA TODAY.
Anthony Hutchinson, who heads public affairs for VantageScore, told USA TODAY that the company's model – the information it compiles on consumers to offer lenders information on their creditworthiness – is 'more holistic' than FICO's.
Among other things, Hutchinson said, VantageScore's model is able to blend consumer information over a period of time. This 'trended' approach is more useful than just looking at a consumer at one moment in time, he argues, because it can show whether that person's financial health is improving or weakening.
VantageScore also claims that there are 33 million Americans who are 'credit invisible' – that is, they have no credit score at all – and whom the company's more modern approaches to collecting data do better at scoring.
But Wu says she doubts those numbers. In fact, the Consumer Financial Protection Bureau recently released research that suggests the number of Americans who are credit invisible is only about one-tenth that estimate, or roughly 2.7 million people. Wu also notes that FICO has also incorporated some of the more dynamic credit attributes VantageScore boasts about.
In response to USA TODAY's request for comment, a FICO spokesperson emailed:
'FICO welcomes competition on a level playing field among credit score providers. We compete vigorously in every U.S. consumer credit market, and the FICO Score is freely chosen by lenders, investors, and other market participants because it is trusted as the most predictive and reliable credit score. FICO scores are the industry standard and preferred choice for evaluating creditworthiness in the mortgage process, regardless of whether the loan is conforming or non-conforming."
Opening up the credit scoring space to real competition – and easing the path to homeownership for more Americans – gets bipartisan support even in a polarized Washington. Pulte's decision had its origins in legislation introduced by Republican Senator Tim Scott (South Carolina) and Democratic Senator Mark Warner (Virginia) years ago, Hutchinson points out.
The legislation, the Credit Score Competition Act, was signed into law in 2018 as part of the Economic Growth, Regulatory Relief, and Consumer Protection Act, but FHFA took several years to decide how to implement it. Senator Scott was one lawmaker urging quicker action on that front, in 2023.
Wu believes the slower approach was for the best, given the number of stakeholders involved in making such a big transition. 'I think changing a well-thought out decision that was the result of a lot of process by an arbitrary tweet is bonkers,'' she said. "I have no idea if it complies with the 2018 law or the regulations, or if it's arbitrary and capricious.'
Aside from concerns about the industry backdrop, VantageScore's presence might not even make a difference for consumers in terms of immediate savings. When asked about how much less one of their scores would cost compared to a FICO score, the company deflected the question to the credit bureaus.Equifax and Experian did not immediately respond to a request for comment, and a TransUnion spokesperson referred USA TODAY to an industry group for more information.
CFA's Cornelissen, despite her support for the step, acknowledges the savings will be minor: in the 'tens of dollars," she said.
Read next: Down payments are the biggest homeownership hurdle. Why is Washington making them scarcer?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Yahoo

timea few seconds ago

  • Yahoo

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Yahoo

timea few seconds ago

  • Yahoo

RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Yahoo

timea few seconds ago

  • Yahoo

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store